FN Clarivate Analytics Web of Science
VR 1.0
PT J
DE Electrospinning; Xeno-free scaffold; Human umbilical cord; Collagen;
   Hyaluronic acid; Vascularization
ID MESENCHYMAL STEM-CELLS; HYALURONIC-ACID; IN-VITRO; PHYSICAL-PROPERTIES;
   ADHESION FORMATION; COLLAGEN; HYDROGEL; ANGIOGENESIS; GELATIN; CULTURE
ER

PT J
DE Cytotoxicity; Cell adhesion; Cell proliferation; Osteogenic
   differentiation; Inflammatory response; Cellular models; Stem cells
ID MESENCHYMAL STEM-CELLS; CHITOSAN-BASED SCAFFOLDS; UMBILICAL-CORD BLOOD;
   ADIPOSE-TISSUE; DENDRITIC CELLS; MAGNETIC-FIELD; OSTEOBLAST
   DIFFERENTIATION; MACROPHAGE POLARIZATION; INFLAMMATORY RESPONSE;
   IMMUNE-RESPONSES
ER

PT J
DE alumina; biocompatibility; cell responses; protein adsorption
ID BODY GIANT-CELLS; PROTEIN ADSORPTION; IN-VITRO; CRYSTALLIZATION
   BEHAVIOR; MECHANICAL-PROPERTIES; CELLULAR-RESPONSES; ISOELECTRIC POINT;
   INNATE IMMUNITY; MAST-CELLS; SURFACE
ER

PT J
DE Probiotic yeasts; Olive oil yeasts; Virgin olive oil
ID SACCHAROMYCES-CEREVISIAE; MULTIFUNCTIONAL FEATURES;
   YAMADAZYMA-TERVENTINA; LIPOLYTIC-ACTIVITY; CANDIDA-ADRIATICA;
   IDENTIFICATION; AGGREGATION; SELECTION; ADHESION; DAIRY
ER

PT J
DE bacterial infection in mussels; copper oxide nanoparticles; hemocytes;
   immune system
ID ENGINEERED NANOMATERIALS; RESPONSES; TOXICITY; HEMOCYTES;
   TRANSFORMATION; ACCUMULATION; PHAGOCYTOSIS; AGGREGATION; DISSOLUTION;
   STABILITY
ER

PT J
DE clonal selection algorithm; complete receptor editing; quantum
   interference crossover; traveling salesman problem;
   holes-machining-path-planning problem
ID PARTICLE SWARM OPTIMIZATION; GENETIC ALGORITHM; IMMUNE ALGORITHM;
   GENERATION; LOCATION; NETWORK; DESIGN
ER

PT J
DE Computer-aided antibody engineering; Affinity improvement; Ibalizumab
ID ANTI-CD4 MONOCLONAL-ANTIBODY; IBALIZUMAB; PHARMACOKINETICS; MATURATION;
   CD4
ER

PT J
DE Hybrid hydrogels; Microporous network; Vaccination; Immune response;
   Lymph node
ID ALBUMIN-BASED NANOPARTICLES; DNA VACCINE; DENDRITIC CELLS;
   IMMUNE-RESPONSES; DELIVERY; DESIGN; MICRONEEDLES; PARTICLES; EFFICACY;
   ANTIGEN
ER

PT J
DE Reverse thermal gel; Neural tube defects; Myelomeningocele; Prenatal
   repair; Biomimetic patch
ID NEURAL-TUBE CLOSURE; TISSUE ENGINEERING APPROACH; IN-UTERO REPAIR;
   SPINA-BIFIDA; PRENATAL CLOSURE; EPIDEMIOLOGY; SURGERY; CELLS;
   EXPRESSION; SCAFFOLDS
ER

PT J
DE Tumor necrosis factor receptor; Anti-TNF effect; Prokaryotic expression;
   Protein refolding; Oligomerization
ID RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; TNF; ETANERCEPT; COMBINATION;
   OUTCOMES; CLONING
ER

PT J
DE Chondrocytes; Hypertrophy; Stem cells; Arthritis; WNT/beta-catenin
   pathway
ID ARTICULAR-CARTILAGE; DIFFERENTIATION; RUNX2; INHIBITION; EXPRESSION;
   CHONDROGENESIS; SCLEROSTIN; DKK-1; SOX9
ER

PT J
DE Angiogenesis; Microfluidics; Blood brain barrier; Permeability
ID BLOOD-BRAIN-BARRIER; VASCULAR-PERMEABILITY; BASEMENT-MEMBRANE;
   PERICYTES; MICROVESSELS; CADHERIN; MODELS; HEALTH
ER

PT J
DE 3D printing; hydrogel; chitosan; inflammation; articular cartilage
ID MESENCHYMAL STEM-CELLS; ARTICULAR-CARTILAGE; IN-VITRO; CHONDROGENIC
   DIFFERENTIATION; DRUG-DELIVERY; CHITOSAN; OSTEOARTHRITIS; REGENERATION;
   SCAFFOLDS; RESPONSES
ER

PT J
DE decellularized spleen matrix; bioartificial liver; hemocompatibility;
   PDADMAC; heparin
ID IMMUNE-RESPONSE; SCAFFOLD; SHORTAGE; HEPARIN; SYSTEMS; CELLS
ER

PT J
DE Sesbania aegyptica; immunotherapy; cancer; silver nanoparticles; PEG
ID IMMUNOTHERAPY; ROOT
ER

PT J
DE Gold nanomaterial; Iodine-124; Radioactive imaging tracers; Positron
   emission tomography; Cerenkov luminescent imaging; Sentinel lymph node
   mapping
ID POSITRON-EMISSION-TOMOGRAPHY; BLUE-DYE; BREAST-CANCER; QUANTUM DOTS;
   NANOPARTICLES; FLUORESCENCE; INJECTION; BIOPSY
ER

PT J
ID T-CELL TOLERANCE; GUANYLYL CYCLASE-C; RESTRICTED ANTIGENS; ANTITUMOR
   EFFICACY; EXPRESSION; IDENTIFICATION; RESPONSES; SELECTION;
   IMMUNOTHERAPY; GENERATION
ER

PT J
ID SPIN-ORBIT TORQUE; HALL; FERROMAGNETISM; MAGNETISM; TRANSITION; CRYSTAL
ER

PT J
ID BROILER-CHICKENS; ALPHA-TOXIN; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE;
   IMMUNE-RESPONSES; IMMUNIZATION; STRAINS; PATHOGENESIS; IDENTIFICATION;
   CHALLENGE; BACTERIA
ER

PT J
DE ST6Gal; ST3Gal; Sialyllactose; Poikilotherm; ELLA; HILIC-HPLC; CHO
   expression; Catalytic domain; Secreted; Glycans
ID BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; LINKED LECTIN ASSAY;
   OLIGOSACCHARIDES; EXPRESSION; BINDING; ALPHA-2,3-SIALYLTRANSFERASE;
   MILK; IDENTIFICATION; SIALYLATION; RECOGNITION
ER

PT J
DE Iron oxide; Nanoparticles; Dendron; Oligoethyleneglycol;
   Biocompatibility; MRI; Theranostic
ID IRON-OXIDE NANOPARTICLES; POLYETHYLENE-GLYCOL PEG; IN-VITRO TOXICITY;
   OXIDATIVE STRESS; CELLULAR UPTAKE; CONTRAST AGENT; SUPERPARAMAGNETIC
   NANOPARTICLES; INORGANIC NANOPARTICLES; MAGNETIC NANOPARTICLES; PROTEIN
   ADSORPTION
ER

PT J
DE HCV; CD81; Retrovirus; E2; E1; Transport
ID IMMUNE-RESPONSES; DNA VACCINES; EXPANSION; REVEALS
ER

PT J
DE Mesenchymal stem cells; 3D encapsulation; Advanced technologies;
   Hydrogel; Tissue regeneration
ID BONE-MARROW; MICROFLUIDIC ENCAPSULATION; HEPATIC DIFFERENTIATION;
   CARTILAGE TISSUE; AMNIOTIC-FLUID; STROMAL CELLS; CULTURE; HYDROGELS;
   MATRIX; GENERATION
ER

PT J
DE Adoptive T-cell therapy; tumour microenvironment; immunotherapy; cancer;
   particulate systems
ID GROWTH-FACTOR-BETA; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE CHECKPOINT
   BLOCKADE; ANTIGEN-PRESENTING CELLS; IMMATURE MYELOID CELLS; IN-VIVO;
   TGF-BETA; GOLD NANOPARTICLES; PHOTOTHERMAL THERAPY; PHOTODYNAMIC THERAPY
ER

PT J
DE Arginase; MDSC; Arginine; Metabolic checkpoint; Aminoacid;
   Immunocompetent; Autochthonous
ID LUNG-CANCER; TUMOR MICROENVIRONMENT; LYMPHOCYTE RATIO; L-ARGININE;
   NIVOLUMAB; CHEMOTHERAPY; NEUTROPHIL; BLOCKADE; EVASION; PEMBROLIZUMAB
ER

PT J
ID T-CELLS; ANTITUMOR IMMUNITY; DOUBLE-BLIND; STAGE-III; RESPONSES;
   SURVIVAL; THERAPY; ELECTROPORATION; IMMUNOGENICITY; SUPPRESSION
ER

PT J
DE immobilized; antibacterial activity; imipenem; gold nanoparticles
ID DNA; CYTOTOXICITY
ER

PT J
DE HIV; Tat; Methamphetamine; TATA-box; TATA-box binding peptide;
   Crispr/Cas9; macrophages; inflammation
ID SIV-INFECTED MACAQUES; IL-10 PRODUCTION; GENE-EXPRESSION; HUMAN
   MONOCYTES; VIRUS; ACTIVATION; PROMOTER; RNA; IDENTIFICATION; TARGET
ER

PT J
ID GENE-TRANSFER; STEM-CELLS; CLINICAL-TRIALS; DOUBLE-BLIND; THERAPY;
   ANGIOGENESIS; SURVIVAL; EFFICACY; DELIVERY; MSC
ER

PT J
DE HCMV; TCR; CD8 T cell; IFN-gamma; Immune response; HSCT
ID TRANSPLANT RECIPIENTS; DISEASE; CHAIN
ER

PT J
DE Bioactive nanoparticles; Peptide; Nanodrug; Anti-inflammatory
   therapeutics; Toll-like receptor signaling; Acute lung injury
ID SPLIT HEPARIN NANOPARTICLES; ENDOTOXIN TOLERANCE; IMMUNE-RESPONSES;
   INFLAMMATION; INDUCTION; PHARMACOKINETICS; ATTENUATION; INTERFERON;
   INFECTION; DENSITY
ER

PT J
DE Recombination-activating gene 2; VDJ recombination; severe combined
   immunodeficiency; Omenn syndrome; autoimmunity; genotype-phenotype
   correlation
ID SEVERE COMBINED IMMUNODEFICIENCY; OMENN-SYNDROME; V(D)J RECOMBINATION;
   IMMUNE-DEFICIENCY; SPECTRUM; DEFECTS; DISEASE; RAG1/2
ER

PT J
DE Bispecific; HIV; Lymph nodes; Cure
ID REGULATORY T-CELLS; BROADLY NEUTRALIZING ANTIBODIES;
   MONOCLONAL-ANTIBODIES; MALIGNANT ASCITES; PASSIVE TRANSFER;
   FC-RECEPTORS; TUMOR-CELLS; CANCER; VIRUS; THERAPEUTICS
ER

PT J
ID BISPECIFIC ANTIBODIES; T-CELLS; MOUSE; BLINATUMOMAB; RECOGNITION;
   GENERATION; REGRESSION; EFFICACY; BINDING; GAMMA
ER

PT J
DE Glioma; Tumorsphere; Microscale niche; Time series assessment; Hypoxic
   stress; Tumor microenvironment array platform
ID GLIOBLASTOMA STEM-CELLS; MICROENVIRONMENTAL REGULATION; MGMT EXPRESSION;
   TUMOR; HETEROGENEITY; RESISTANCE; INDUCTION; INVASION; CULTURE; THERAPY
ER

PT J
ID CHRONIC MYELOID-LEUKEMIA; COMPLETE MOLECULAR REMISSION; KINASE INHIBITOR
   THERAPY; SUICIDE GENE; IMATINIB; DISCONTINUATION; TRANSPLANTATION;
   NILOTINIB; RELAPSE; IMPROVE
ER

PT J
ID HEMATOPOIETIC STEM-CELLS; CHIMERIC ANTIGEN RECEPTORS; GENE-THERAPY;
   T-CELLS; CANCER REGRESSION; EXPRESSION; LYMPHOCYTES; VECTOR;
   TRANSPLANTATION; RECONSTITUTION
ER

PT J
ID FOXO TRANSCRIPTION FACTORS; L-SELECTIN; MEMORY; SURVIVAL; RAPAMYCIN;
   EFFECTOR; THERAPY; AKT; ACTIVATION; EXPRESSION
ER

PT J
DE Naive T cells; T-Lymphocyte Subsets; Graft-versus-host disease; Graft
   engineering; Selective T cell depletion
ID VERSUS-HOST-DISEASE; RECEPTOR CCR7 INCREASES; ADOPTIVE IMMUNOTHERAPY;
   EFFECTOR-MEMORY; ACUTE-LEUKEMIA; BONE-MARROW; NAIVE; TRANSPLANTATION;
   STIMULATION; POPULATIONS
ER

PT J
DE nanomaterials; immune system; stealth; biomimetic; bio-corona; targeting
ID TUMOR-ASSOCIATED MACROPHAGES; NANOPARTICLE-PROTEIN CORONA; SCAVENGER
   RECEPTOR MARCO; WALLED CARBON NANOTUBES; ENGINEERED NANOMATERIALS;
   THERAPEUTIC NANOPARTICLES; CANCER NANOMEDICINE; BIOMOLECULAR CORONA;
   GOLD NANOPARTICLES; RECOGNITION
ER

PT J
DE M cell; Engineered materials; Mucosal vaccination; Mucosa-associated
   lymphoid tissues; Antibody response; Peyer's patch; Targeted delivery
   systems
ID FOLLICLE-ASSOCIATED EPITHELIUM; PATCH M-CELLS; INTESTINAL M-CELLS;
   THIOLATED EUDRAGIT MICROSPHERES; ATTENUATED SALMONELLA VACCINES;
   ISOLATED LYMPHOID FOLLICLES; III SECRETION SYSTEM; MEMBRANOUS M CELLS;
   MUCOSAL B-CELL; PEYERS-PATCH
ER

PT J
DE FasL; Immune tolerance; PLG; Polymer scaffold; Allogeneic; Islet
   transplantation
ID REGULATORY T-CELLS; ISLET ALLOGRAFT-REJECTION; PANCREATIC BETA-CELLS;
   LIGAND EXPRESSION; POLYMER SCAFFOLDS; CD95 LIGAND; NOD MICE; IN-VITRO;
   APOPTOSIS; TRANSPLANTATION
ER

PT J
DE Tissue engineering; Regenerative medicine; Immunology; Macrophages; T
   cells
ID SMALL-INTESTINAL SUBMUCOSA; FOREIGN-BODY RESPONSE; SMOOTH MUSCLE ACTIN;
   MACROPHAGE POLARIZATION; BIOMATERIAL; IMPLANTS; RODENTS
ER

PT J
DE Tissue engineering; Brain tissue; Brain damage; Transplantation;
   Neuroinflammation; Cortical tissue
ID HIGH-DOSE METHYLPREDNISOLONE; STEM-CELLS; REACTIVE ASTROCYTES; INJURY;
   MICROGLIA; NEUROINFLAMMATION; REGULATOR; SURVIVAL; NEURONS; ORIGIN
ER

PT J
DE Human bone marrow derived mesenchymal stromal cells; Chondrogenesis;
   Selection markers; Tissue engineering; RNA sequencing; NCAM1/CD56
ID STEM-CELLS; IN-VITRO; EXPRESSION; QUANTIFICATION; RECEPTOR
ER

PT J
DE Lipopolysaccharide (LPS); Structure elucidation; NMR; Mass spectrometry;
   Glucuronic acid
ID RHODOPSEUDOMONAS-SPHAEROIDES; LIPID-A; ENDOTOXIN ANTAGONIST;
   FATTY-ACIDS; LIPOPOLYSACCHARIDE; TLR4; LPS
ER

PT J
DE Poria cocos; Immunomodulatory protein; Pichia pastoris; Purification;
   N-Glycosylation; Bioactivity assay
ID MOLECULAR-CLONING
ER

PT J
DE Macrophages; Vascularization; Vessel development; Macrophage phenotypes;
   Tissue engineering
ID ANTIINFLAMMATORY MONOCYTES; SECRETORY PRODUCTS; ENDOTHELIAL-CELLS;
   ANGIOGENESIS; POLARIZATION; RECRUITMENT; GROWTH; REPAIR;
   NEOVASCULARIZATION; HIF-1-ALPHA
ER

PT J
ID HEMATOPOIETIC PROGENITORS; SPECIFICATION; REGENERATION; PRECURSOR;
   IPSCS; FATE; BANK
ER

PT J
DE Photobiomodulation; Low level light therapy; Mesenchymal stem cells;
   bone; Cartilage; Comparison of wavelengths
ID BIPHASIC DOSE-RESPONSE; IN-VITRO; PROMOTES PROLIFERATION; IRRADIATION;
   THERAPY; OSTEOBLASTS; PHOTOTHERAPY
ER

PT J
DE Hepatitis C virus; NS3; Helicase; Immunodiagnostic; Seroconversion
ID NON-A; MUTATIONAL ANALYSIS; HCV; INFECTION; ANTIGEN; DONORS; RNA
ER

PT J
DE CRISPR-Cas systems; Adaptive immunity; Self versus non-self
   discrimination; Lamarckian evolution; Horizontal gene transfer
ID HORIZONTAL GENE-TRANSFER; SPACER ACQUISITION; ADAPTIVE IMMUNITY;
   FUNCTIONAL-CHARACTERIZATION; NUCLEASE ACTIVITY; DEFENSE SYSTEMS; CAS2
   PROTEIN; DNA; RNA; VIRUSES
ER

PT J
DE 3D human placenta-on-a-chip; Nanoparticle exposure; Organ-on-a -chip
ID INFLAMMATION
ER

PT J
DE 3D printing; porous tracheal scaffold; PCL; surface modifications;
   tissue engineering
ID REPLACEMENT; DESIGN; FUSION; GRAFT
ER

PT J
DE Lymphangiogenesis; Tissue Engineering; Disease Modeling; Wound Healing;
   Lymphedema; Stem Cells; Biomaterials; Interstitial Fluid; Regeneration
ID GROWTH-FACTOR-C; CEREBRAL AMYLOID ANGIOPATHY; PLURIPOTENT STEM-CELLS;
   ENDOTHELIAL PROGENITOR CELLS; HUMAN ADIPOSE-TISSUE; ACID-BASED HYDROGEL;
   VEGF-C; INTERSTITIAL FLOW; SMOOTH-MUSCLE; IN-VITRO
ER

PT J
ER

PT J
ER

PT J
ER

PT J
ER

PT J
DE Oncolytic viruses; Immune therapy; Transgenes
ID NEWCASTLE-DISEASE-VIRUS; HERPES-SIMPLEX-VIRUS; VESICULAR
   STOMATITIS-VIRUS; COLONY-STIMULATING FACTOR; SQUAMOUS-CELL CARCINOMA;
   GM-CSF; CANCER-IMMUNOTHERAPY; VACCINIA VIRUS; T-CELLS; CHECKPOINT
   BLOCKADE
ER

PT J
ID IMPLANTATION
ER

PT J
DE cancer immunotherapy; cell therapy; drug delivery; immune checkpoint
   blockade; nanomedicine
ID MEMBRANE-COATED NANOPARTICLES; DRUG-DELIVERY SYSTEMS; T-CELL;
   INDOLEAMINE 2,3-DIOXYGENASE; EXTRACELLULAR VESICLES; MIMETIC
   NANOVESICLES; ANTI-PD-L1 ANTIBODY; ADVANCED MELANOMA; IN-VIVO; THERAPY
ER

PT J
ER

PT J
DE B cell; CD47; human; humanized mouse; macrophage; miniature swine; mixed
   chimerism; mouse; natural antibody; natural killer cell; pig; rat; T
   cell; thymus; tolerance; xenotransplantation
ID MIXED XENOGENEIC CHIMERAS; PORCINE ENDOTHELIAL-CELLS; ANTIBODY-PRODUCING
   CELLS; THYMIC EPITHELIAL-CELLS; NATURAL-KILLER-CELLS; BONE-MARROW-CELLS;
   NONMYELOABLATIVE CONDITIONING REGIMEN; NONLETHAL PREPARATIVE REGIMEN;
   PROMISCUOUS GENE-EXPRESSION; CARDIAC XENOGRAFT SURVIVAL
ER

PT J
ID ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; TOLEROGENIC DENDRITIC
   CELLS; TUMOR-ASSOCIATED MACROPHAGES; EX-VIVO EXPANSION; IN-VIVO; HUMAN
   IMMUNOLOGY; DRUG-DELIVERY; COMPLEMENT ACTIVATION; VACCINE-DELIVERY
ER

PT J
DE Intelligent manufacturing system; Immune monitoring model; Immune
   assessment; Immune response
ID BIOLOGICAL-SYSTEMS; INSPECTION
ER

PT J
DE allogeneic; immunomodulation; immunogenicity; osteogenic; chondrogenic
   MSCs; tissue engineering
ID MARROW STROMAL CELLS; ENDOCHONDRAL OSSIFICATION; IN-VITRO; DENDRITIC
   CELLS; CHONDROGENIC DIFFERENTIATION; IMMUNOMODULATORY PROPERTIES;
   IMMUNOLOGICAL-PROPERTIES; ARTICULAR-CARTILAGE; ADULT HUMAN; REGENERATION
ER

PT J
DE Nanogold; rheumatoid arthritis; inflammation; transcription factor
ID COLLAGEN-INDUCED ARTHRITIS; NANOPARTICLES; CANCER; EXPRESSION;
   INFLAMMATION; ANTIOXIDANTS; CHEMOKINES; SCATTERING; CARTILAGE; CYTOKINES
ER

PT S
ER

PT J
DE Immune subsets; Allografts; Outcomes; Graft-versus-host disease; Relapse
ID VERSUS-HOST-DISEASE; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS;
   BONE-MARROW-TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; HLA-IDENTICAL
   SIBLINGS; NATURAL-KILLER-CELLS; PERIPHERAL-BLOOD; HEMATOLOGIC
   MALIGNANCIES; IMPROVED SURVIVAL
ER

PT J
ID MESENCHYMAL STEM-CELLS; ELECTRON-BEAM LITHOGRAPHY;
   TUMOR-NECROSIS-FACTOR; MICE LACKING INTERLEUKIN-10; TITANIUM-DIOXIDE
   NANOTUBES; IN-VIVO OSSEOINTEGRATION; HIGH BONDING STRENGTH;
   OSTEOBLAST-LIKE CELLS; IMMUNE-RESPONSE; OSTEOGENIC DIFFERENTIATION
ER

PT J
DE Innate immunity; Engineered nanoparticles; Inflammation; Immunosafety;
   Toxicity; Complement
ID WALLED-CARBON-NANOTUBES; NEUTROPHIL EXTRACELLULAR TRAPS;
   TUMOR-ASSOCIATED MACROPHAGES; NONCANONICAL INFLAMMASOME ACTIVATION;
   DISCOIDAL POLYMERIC NANOCONSTRUCTS; MEDIATED COMPLEMENT ACTIVATION;
   METAL-OXIDE NANOPARTICLES; DENDRITIC CELLS; IN-VIVO; ENGINEERED
   NANOMATERIALS
ER

PT J
DE Artificial immune system; Hybridization; Optimization; Identification;
   Mechanical systems
ID NETWORK; SELECTION; ALGORITHMS; MODEL
ER

PT J
DE Tissue engineering; Tissue-engineered vascular graft; Congenital cardiac
   disease; Surgery; Fontan; Bone marrow-derived mononuclear cells
ID BONE-MARROW-CELLS; PULMONARY-ARTERY; AUTOGRAFTS; MODEL; TRANSPLANTATION;
   STENOSIS; CULTURE
ER

PT J
DE bacteria; biomimetic engineering; cancer immunotherapy; particulate
   adjuvant; vaccines
ID ADVANCED MELANOMA; MANNOSE RECEPTOR; DENDRITIC CELLS; NANOPARTICLES;
   VACCINES; IMMUNITY; INTERLEUKIN-2; IMMUNOTHERAPY; PHAGOCYTOSIS;
   AUTOPHAGY
ER

PT J
ER

PT J
DE Tissue engineering; Engineered heart muscle; Pluripotent stemcells;
   Regeneration; Remuscularization; Heart failure; Transplant immunology
ID LEFT-VENTRICULAR FUNCTION; STEM-CELLS; HEART-FAILURE; ISCHEMIC
   CARDIOMYOPATHY; INTERNATIONAL SOCIETY; CARDIAC PROGENITORS; SKELETAL
   MYOBLASTS; INFARCTION; TRANSPLANTATION; MUSCLE
ER

PT J
ER

PT J
ER

PT J
DE immunology; inflammation; polymeric scaffolds; tissue engineering
ID MESENCHYMAL STEM-CELLS; PEDIATRIC CARDIAC-SURGERY; FOREIGN-BODY
   REACTION; IN-VITRO; MACROPHAGE POLARIZATION; CARDIOPULMONARY BYPASS;
   PROTEIN ADSORPTION; IMMUNE-RESPONSE; T-CELLS; PROINFLAMMATORY CYTOKINES
ER

PT J
DE Organoids; Hydrogel; Spatio-temporal; Adhesive; Lymph node;
   Microfluidics
ID T-CELL DEVELOPMENT; RECEPTOR-LIGAND INTERACTIONS; ANTIBODY-BASED
   IMMUNOTHERAPY; HEMATOPOIETIC STEM-CELLS; THYMIC EPITHELIAL-CELLS;
   B-CELL; GERMINAL-CENTER; NOTCH-LIGAND; LYMPHOID ORGANS; IN-VIVO
ER

PT J
ER

PT J
ER

PT J
DE editorial; personal viewpoint; immunobiology; immunosuppression; immune
   modulation; immune regulation; tolerance: experimental
ID RECEPTOR
ER

PT J
DE Tissue engineered scaffolds; Inflammatory responses; Protein; Cytokines;
   Stem cells; Macrophages; Fibrocytes; Tissue regeneration; Foreign body
   reactions
ID ACUTE INFLAMMATORY RESPONSES; FOREIGN-BODY REACTION; BONE MORPHOGENETIC
   PROTEINS; LONG-TERM DEGRADATION; IN-VIVO; POLY(L-LACTIC ACID);
   REGENERATIVE MEDICINE; TISSUE RESPONSES; BIOMATERIALS; MACROPHAGE
ER

PT J
ID BIOLOGICAL IDENTITY; NANOPARTICLE UPTAKE; SURFACE; RECEPTOR; LINES; SIZE
ER

PT J
DE T cellular immunotherapies; Hepatocellular carcinoma; Immune checkpoint
   blockade; T cell receptor-engineered T cells; Chimeric antigen
   receptor-engineered T cells; Bispecific T cell engagers
ID INDUCED KILLER-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE CHECKPOINT
   BLOCKADE; CHIMERIC ANTIGEN RECEPTORS; HEPATITIS-B-VIRUS; ADOPTIVE
   IMMUNOTHERAPY; ANTITUMOR IMMUNITY; DENDRITIC CELLS; CLINICAL-TRIAL;
   SOLID TUMORS
ER

PT J
DE adjuvant; exosomes; Nef; HPV-E6; CD8(+) T immune response
ID VIRUS-LIKE PARTICLES; CROSS-PRESENTATION; DENDRITIC CELLS; INDUCTION;
   PROTEIN; E7
ER

PT J
ER

PT J
ID DEPENDENT CELLULAR CYTOTOXICITY; LENGTH IGG ANTIBODIES; IN-VIVO
   ACTIVITY; MONOCLONAL-ANTIBODY; EFFECTOR FUNCTIONS; HALF-LIFE; GAMMA-RI;
   ENGINEERED ANTIBODIES; ANTITUMOR-ACTIVITY; RECRUIT COMPLEMENT
ER

PT J
DE antibodies; Fab fragments; monobodies; nanobodies; protein engineering
ID NEONATAL FC-RECEPTOR; SINGLE-DOMAIN ANTIBODIES; BREAST-CANCER;
   CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES;
   BINDING-PROTEINS; LIVING CELLS; CHAIN FV; IN-VIVO
ER

PT J
ER

PT J
DE T cell; T cell receptor (TCR); Chimeric antigen receptor (CAR);
   Gene-modified T cells; Adoptive cell therapy; Tumor immunity
ID CHIMERIC-ANTIGEN-RECEPTOR; TUMOR-INFILTRATING LYMPHOCYTES; MAJOR
   HISTOCOMPATIBILITY COMPLEX; VERSUS-HOST-DISEASE; IN-VIVO PERSISTENCE;
   METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; ADOPTIVE TRANSFER; PHASE-I;
   CLINICAL-TRIAL
ER

PT J
ID PREVENT XENOGRAFT REJECTION; ISLET-CELL TRANSPLANTATION;
   PROOF-OF-CONCEPT; DELTA-T-CELL; IN-VIVO; REGENERATIVE MEDICINE;
   EXTRACELLULAR-MATRIX; NEONATAL DESENSITIZATION; MACROPHAGE PHENOTYPE;
   CLINICAL-APPLICATION
ER

PT J
DE Immuno-engineering; biomaterials; autoimmune disease; particulate;
   immunotherapy; tolerogenic
ID REGULATORY T-CELLS; TOLEROGENIC DENDRITIC CELLS; PLASMA-PROTEIN
   ADSORPTION; INFLAMMATORY-DISEASES; NEGATIVE SELECTION;
   CROSS-PRESENTATION; POLYMER PARTICLES; IMMUNE-SYSTEM; LYMPH-NODES;
   EX-VIVO
ER

PT J
ID PROTEIN; RECOGNITION; ARABIDOPSIS; EFFECTOR; CLEAVAGE
ER

PT J
DE xenotransplantation; genome; engineering; editing
ER

PT J
DE immunocytokines; bispecific antibodies; immunotherapy of cancer;
   antibody engineering; armed antibodies
ID CYTOKINE FUSION PROTEINS; I CLINICAL-TRIAL; ACUTE
   LYMPHOBLASTIC-LEUKEMIA; MEDIATED TARGETED DELIVERY; POTENT
   ANTITUMOR-ACTIVITY; SINGLE-CHAIN ANTIBODY; ED-B DOMAIN; CANCER-PATIENTS;
   NECROSIS-FACTOR; PHASE-I
ER

PT S
DE fault diagnosis; artificial immune algorithm; Selective ensemble
   learning algorithm; Support vector machines; Bagging
ER

PT J
ER

PT J
ID PEGYLATED LIPOSOMAL DOXORUBICIN; CYTOKINE RELEASE SYNDROME; COMPLEMENT
   ACTIVATION; NALP3 INFLAMMASOME; DENDRITIC CELLS; IN-VIVO; GOLD
   NANOPARTICLES; POLYMERIC NANOPARTICLES; SILVER NANOPARTICLES; BLOOD
   COMPATIBILITY
ER

PT J
DE Tissue engineering; Immune modulation; Immune system; Cell
   transplantation; Biomaterials; Gene delivery; Nanoparticles; T cells;
   Stem cells
ID REGULATORY T-CELLS; SPINAL-CORD-INJURY; MESENCHYMAL STEM-CELLS; NEURAL
   STEM/PROGENITOR CELLS; DONOR SPLENOCYTE INFUSIONS; COLONY-STIMULATING
   FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRAHEPATIC ISLET
   TRANSPLANTATION; EXPERIMENTAL MYASTHENIA-GRAVIS; NILE-VIRUS ENCEPHALITIS
ER

PT J
ER

PT J
DE Implant; Macrophage; Scaffold; Stem cell; Tissue engineering
ID MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; PEDIATRIC CARDIAC-SURGERY;
   EXTRACELLULAR-MATRIX; IMMUNE-RESPONSE; MACROPHAGE POLARIZATION;
   CARDIOPULMONARY BYPASS; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; IFN-GAMMA
ER

PT J
ER

PT J
ER

PT J
ID STEM-CELL TRANSPLANTATION; NATURAL-KILLER-CELLS; VERSUS-HOST-DISEASE;
   BONE-MARROW-TRANSPLANTATION; NAIVE T-CELLS; HEMATOLOGIC MALIGNANCIES;
   POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; IMMUNE RECONSTITUTION;
   ACUTE-LEUKEMIA; NK CELLS
ER

PT J
ID HUMAN IMMUNOLOGY; MASS CYTOMETRY; RESPONSES; IMMUNE; IMMUNOTHERAPY;
   MIATA
ER

PT J
DE Engineered heart tissue; Rat; Immune response; Scaffold; Rejection;
   Bioluminescence imaging
ID IMPROVES CARDIAC-FUNCTION; MYOCARDIAL-INFARCTION; MYOBLAST
   TRANSPLANTATION; CARDIOMYOCYTE SHEETS; COLLAGEN IMPLANT; HOST RESPONSE;
   STEM-CELLS; MATRIX; REGENERATION; PERFUSION
ER

PT J
ER

PT J
ER

PT J
ER

PT J
DE Heart valve tissue engineering; Decellularization; Cellular reseeding;
   Xenograft rejection; Inflammatory immune response; Macrophages
ID EARLY FAILURE
ER

PT J
DE Biomaterials; Immune cells; Vascularization
ID ENDOTHELIAL GROWTH-FACTOR; MAST-CELL TRYPTASE; COLLATERAL VESSEL
   DEVELOPMENT; FOREIGN-BODY REACTION; CD4(+) T-CELLS; DENDRITIC CELLS;
   IN-VIVO; MACROPHAGE POLARIZATION; EXTRACELLULAR MATRICES; ARTERIOGENIC
   RESPONSE
ER

PT J
ID HEMOPHILIA-A; TOLERANCE
ER

PT J
DE immunotherapy; glioblastoma; vaccines; antibodies; monoclonal;
   checkpoint modulators; T cell engineering
ID CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR RECEPTOR; HEAT-SHOCK-PROTEIN;
   NEWLY-DIAGNOSED GLIOBLASTOMA; CYTOTOXIC T-LYMPHOCYTES; FIXED TUMOR
   VACCINE; RECURRENT GLIOBLASTOMA; HUMAN CYTOMEGALOVIRUS;
   CANCER-IMMUNOTHERAPY; ADVANCED MELANOMA
ER

PT J
DE Fault detection; fault diagnosis; distributed artificial intelligent;
   intelligent maintenance systems; artificial immune systems
ER

PT J
DE Spinal cord injury; Inflammation; Tissue engineering
ID NEURAL STEM/PROGENITOR CELLS; REGULATORY T-CELLS; COLONY-STIMULATING
   FACTOR; MULTIPLE-CHANNEL BRIDGES; IMPROVES FUNCTIONAL RECOVERY;
   MESENCHYMAL STEM-CELLS; FOREIGN-BODY REACTION; NECROSIS-FACTOR-ALPHA;
   MACROPHAGE ACTIVATION; GROWTH-FACTOR
ER

PT S
DE immunoengineering; vaccination; immunotherapy
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SECONDARY LYMPHOID ORGANS;
   ADAPTIVE IMMUNE-RESPONSES; DENDRITIC CELL MATURATION; ANTIGEN-PRESENTING
   CELL; REGULATORY T-CELLS; DRUG-DELIVERY; IN-VITRO; POLYMERIC
   NANOPARTICLES; CONTROLLED-RELEASE
ER

PT J
ER

PT J
ID HUMAN-CELLS; CAS SYSTEM
ER

PT S
DE mechanical and electrical equipment; self-healing; immune principle;
   modeling
ER

PT J
DE nanoparticles; immune system; immunosuppression; inflammation;
   anti-inflammatory properties; immune inhibition
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DELAYED-TYPE
   HYPERSENSITIVITY; SOLID LIPID NANOPARTICLES; ENCAPSULATING BETAMETHASONE
   PHOSPHATE; RHEUMATOID-ARTHRITIS; OXIDE NANOPARTICLES; DENDRITIC CELLS;
   CYCLOSPORINE-A; CONCISE GUIDE; IN-VIVO
ER

PT J
ER

PT B
DE Awareness; Autonomic Computing; Artificial Immune Systems
ER

PT S
ID PARTICLE SWARM OPTIMIZATION; ARTIFICIAL NEURAL-NETWORKS; ANT COLONY
   OPTIMIZATION; ACTIVE VIBRATION CONTROL; FUZZY-LOGIC CONTROLLER; ECONOMIC
   LOAD DISPATCH; INVERSE KINEMATICS PROBLEM; FINITE-ELEMENT MODELS;
   ROTOR-BEARING SYSTEM; GENETIC-ALGORITHM
ER

PT B
DE Artificial Immune System; Clonal Selection Algorithm; Multi-Objectice
   Optimization
ID EVOLUTIONARY ALGORITHMS
ER

PT S
DE aero-engine; fault diagnosis; artificial immune theory; oil analysis;
   wear
ID SYSTEM
ER

PT J
DE macrophage; cancer; antibody; CD47; SIRPa; immunotherapy; phagocytosis;
   immune checkpoint; molecular engineering
ID CD47; PROTEIN; TARGET
ER

PT J
ER

PT B
DE rockbolts; nondestructive detection; immune danger theory
ER

PT B
DE fault diagnosis; nonnegative matrix factorization; artificial immune
   system; time-frequency image
ER

PT S
DE Relative Warmth Index; transitional spaces; non-steady state thermal
   environment; optimization
ER

PT S
DE micropatterning; epithelial; T lymphocyte; immune synapse
ID SUPPORTED LIPID-BILAYERS; DIP-PEN NANOLITHOGRAPHY;
   EPITHELIAL-MESENCHYMAL TRANSITIONS; LASER-SCANNING LITHOGRAPHY; T-CELLS;
   IMMUNOLOGICAL SYNAPSE; SPINDLE ORIENTATION; ADHESION PROTEINS; RECEPTOR
   CLUSTER; ACTIVATION
ER

PT J
DE Artificial immune system; Particle swarm optimization; Optimization;
   Engineering problem; Diversity
ER

PT J
ER

PT J
DE Specific immunotherapy; Guided Missile; Myasthenia gravis; Dendritic
   cells; Fas ligand; Genetic engineering
ID T-CELL RECOGNITION; HUMAN ACETYLCHOLINE-RECEPTOR; DENDRITIC CELLS; FAS
   LIGAND; NEUROMUSCULAR-JUNCTION; IMMUNE REGULATION; ALPHA-SUBUNIT; MICE;
   APOPTOSIS; ANTIGEN
ER

PT J
DE Baculovirus; Adipose-derived stem cells; Inflammation; Immune response;
   Segmental bone defect; Tissue engineering
ID MESENCHYMAL STEM-CELLS; CONSTITUTIVELY ACTIVE FORM; GENE DELIVERY
   VECTOR; MORPHOGENETIC PROTEIN-2; CALVARIAL DEFECTS; MAMMALIAN-CELLS;
   STROMAL CELLS; MOUSE MODEL; EXPRESSION; REPAIR
ER

PT J
DE Artificial immune system; Clonal selection; Fault diagnosis; Fuzzy K-NN;
   Classification
ID CURRENT SIGNATURE ANALYSIS; BROKEN ROTOR BARS; INDUCTION-MOTORS; STATOR
   CURRENT; TRANSFORM; ALGORITHM; DIAGNOSIS; MACHINES; HILBERT
ER

PT J
ER

PT J
ER

PT J
ER

PT J
ID DRUG-DELIVERY; GOLD NANOPARTICLES; SURFACE-PROPERTIES; DENDRITIC CELLS;
   NANO; TOLERANCE; EVOLUTION; TOXICITY; SYSTEMS; DANGER
ER

PT S
DE Immune Genetic Algorithm (IGA); BP neural network model; dynamic
   deformation monitoring; antibody encoding
ER

PT S
DE Artificial immunity; Independent Components Analysis; AIS-ICA; fault
   diagnosis
ER

PT J
DE genetic engineering; scid; acquired immunity; innate immunity;
   pathogens; immunodeficiency; inbred mice; immunophenotype; phenotype;
   GEM
ID MAJOR HISTOCOMPATIBILITY COMPLEX; VIRULENT MYCOBACTERIUM-TUBERCULOSIS;
   PATTERN-RECOGNITION RECEPTORS; SYNCYTIAL VIRUS-INFECTION;
   NATURAL-KILLER-CELLS; REGULATORY T-CELLS; CLASS-II MOLECULES;
   CATHEPSIN-E; NKT CELLS; HELICOBACTER-HEPATICUS
ER

PT J
ER

PT J
ER

PT J
DE adoptive T cell therapy; T cell receptor; graft versus leukaemia; graft
   versus host disease; gene-modified T cells
ID GRAFT-VERSUS-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; MINOR
   HISTOCOMPATIBILITY ANTIGENS; SEVERE COMBINED IMMUNODEFICIENCY; SUPERIOR
   ANTITUMOR IMMUNITY; CHRONIC MYELOID-LEUKEMIA; CLASS-I MOLECULES;
   HOST-DISEASE; METASTATIC MELANOMA; ADOPTIVE TRANSFER
ER

PT J
DE tissue engineering; transplantation; immune response; MHC class I; gene
   therapy; Kaposi's sarcoma-associated herpesvirus; retroviral gene
   expression
ID EMBRYONIC STEM-CELLS; ISLET ALLOGRAFT SURVIVAL; GENE-THERAPY;
   DOWN-REGULATION; LENTIVIRAL VECTOR; REJECTION; PROTEINS; GENOTOXICITY;
   INFLAMMATION; CYTOTOXICITY
ER

PT J
ER

PT S
DE Artificial immune system; learning; hierarchy; antigen; clonal
   selection; lymphocyte; stimulation treshold
ER

PT S
DE Ship parts; Remaining rectangle matching; Particle swarm algorithm
   (PSA); Immune ant colony algorithm
ID SYSTEM
ER

PT J
DE artificial immune systems; constrained optimization; metaheuristics;
   engineering optimization
ID ARTIFICIAL IMMUNE-SYSTEM; CLONAL SELECTION; TOLERANCE; MODEL
ER

PT J
ER

PT J
DE Heart valve; Biocompatibility; Extracellular matrix; Cell proliferation;
   Inflammation
ID SMALL-INTESTINAL SUBMUCOSA; ABDOMINAL-WALL REPAIR; HEART-VALVES;
   DECELLULARIZED PORCINE; HOST RESPONSE; PRIMATE MODEL; ALPHA-GAL;
   T-CELLS; TISSUE; RECEPTOR
ER

PT J
ER

PT J
ER

PT J
DE Cartilage tissue engineering; Foreign body response; Immune response;
   Immunomodulation; Polylactic acid; Scaffold
ID MIGRATION-INHIBITORY FACTOR; FOREIGN-BODY REACTION; GROWTH-FACTOR-BETA;
   PROTEOGLYCAN DEGRADATION; IMMUNE DEVIATION; PRIVILEGED SITES; FAS
   LIGAND; TGF-BETA; IN-VIVO; TRANSPLANTATION
ER

PT S
DE Finite element; mesh-distortion; isoparametric; shape functions; element
   shape
ID AREA COORDINATE METHOD; ISOPARAMETRIC ELEMENTS; PLANE; ACCURACY;
   COMPLETENESS; FAMILY
ER

PT B
DE Machine Learning; Artificial Immune System; frequency-variable air
   conditioner
ER

PT S
DE Artificial Immune System; optimization; identification; parallel
   computing; composite; laminate
ID DESIGN
ER

PT J
ID DENDRITIC-CELL SUBSETS; LIVING EMULSION POLYMERIZATION; IN-VIVO;
   T-CELLS; COMPLEMENT ACTIVATION; DRUG-DELIVERY; NALP3 INFLAMMASOME;
   ADAPTIVE IMMUNITY; ANTIBODY-RESPONSE; BLOCK-COPOLYMER
ER

PT B
DE motor fault diagnosis; wavelet energy; artificial immune system; RBF
   neural network
ER

PT S
DE Artificial immune system; parametric modelling; flexible plate
ER

PT B
DE immune clustering; electric load; division
ER

PT B
DE packing optimization; niche skill; immune genetic algorithm
ER

PT J
ID KAPPA-B ACTIVATION; DELAYED-TYPE HYPERSENSITIVITY; MESENCHYMAL
   STEM-CELLS; REGULATORY T-CELLS; RENAL-TRANSPLANT RECIPIENTS;
   FOREIGN-BODY RESPONSE; ANTI-HLA ANTIBODIES; TOLL-LIKE RECEPTORS;
   IN-VITRO CULTURE; DENDRITIC CELLS
ER

PT J
ER

PT J
DE mesenchymal stem cells; Flt3 ligand; expansion
ER

PT J
ID ELECTRICALLY CONDUCTING POLYMER; GROWTH-FACTOR DELIVERY; DENDRITIC
   CELLS; EXTRACELLULAR-MATRIX; ALGINATE HYDROGELS; ORTHOPEDIC
   APPLICATIONS; MECHANICAL-PROPERTIES; RECEPTOR AGONISTS; DRUG-DELIVERY;
   IN-VITRO
ER

PT J
DE natural immune systems; artificial immune systems; artificial immune
   networks; learning algorithm; data mining
ID SYSTEM; CLASSIFICATION
ER

PT J
DE immunotherapy; composite scaffold; PEG-collagen; cell migration
ID LYMPHOID-TISSUE CHEMOKINE; 3-D EXTRACELLULAR-MATRIX; MATURE DENDRITIC
   CELLS; GROWTH-FACTOR DELIVERY; T-LYMPHOCYTES; IN-VIVO; ANTITUMOR
   IMMUNITY; NODE CORTEX; ADHESION; ANTIGEN
ER

PT J
ER

PT J
ER

PT J
ER

PT B
DE dynamic characteristic clustering; fuzzy artificial immune network
   (FaiNet); load classification
ER

PT B
DE Dynamic clustering; Artificial immune network; Kernel-based possibility
   clustering; Genetic algorithm; Power transformer; Fault diagnosis
ER

PT J
ID FC-GAMMA RECEPTOR; DEPENDENT CELLULAR CYTOTOXICITY;
   NATURAL-KILLER-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING
   FACTOR; NON-HODGKINS-LYMPHOMA; MESSENGER-RNA LEVELS; HAMSTER OVARY
   CELLS; IN-VIVO; MONOCLONAL-ANTIBODIES
ER

PT J
DE stem cells; tolerance; immune response; regenerative medicine; tissue
   engineering
ID MARROW STROMAL CELLS; MONOXIDE-RELEASING MOLECULES; REGENERATE INFARCTED
   MYOCARDIUM; HEME OXYGENASE-1 EXPRESSION; IN-UTERO TRANSPLANTATION; VALVE
   INTERSTITIAL-CELLS; HUMAN ADIPOSE-TISSUE; ENDODERM-LIKE CELLS;
   BONE-MARROW; PROGENITOR CELLS
ER

PT J
ER

PT B
DE electromagnetic radiation; radiation intensity; immune system
ER

PT B
ID CLASSIFICATION
ER

PT B
DE immune feedback control; immune system; main steam temperature system;
   thermal power engineering
ER

PT J
DE artificial immune system; autonomous guided vehicle; multi-agent control
   framework; intelligent material handling system; simulation
ER

PT J
ER

PT B
DE freeway; ramp metering; artificial immune controller; traffic flow model
ER

PT S
DE immune system; artificial immune system; immune engineering; natural
   immune system; artificial immune algorithm
ER

PT J
ER

PT J
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONHUMAN-PRIMATES; VECTORS
ER

PT B
ER

PT J
ER

PT J
DE reconstructive surgery; tissue engineering; cartilage; polyelectrolyte
   complex membrane; macroencapsulation
ID RECONSTRUCTIVE SURGERY; ARTICULAR-CARTILAGE; NECK-SURGERY; IMPLANTS;
   ENCAPSULATION; CHONDROCYTES; SCAFFOLDS; HEAD
ER

PT J
ER

PT J
DE xenotransplantation; pig; primate; humoral rejection; genetic
   engineering; coagulation; safety
ID PORCINE ENDOGENOUS RETROVIRUSES; ACUTE VASCULAR REJECTION; PRIMATE RENAL
   XENOTRANSPLANTATION; DECAY-ACCELERATING FACTOR; GENE-KNOCKOUT PIGS;
   B-CELL TOLERANCE; ENDOTHELIAL-CELLS; TRANSGENIC PIGS; T-CELL;
   TRANSMISSION CHARACTERISTICS
ER

PT J
DE immune system; statistical mechanics; original antigenic sin
ID ORIGINAL ANTIGENIC SIN; DENGUE HEMORRHAGIC-FEVER; TUMOR ESCAPE; VIRUS;
   IMMUNODOMINANCE; CHALLENGES; RESPONSES; VACCINES; MEMORY
ER

PT S
ID OUTPUT PARAMETRIC MODELS; NON-LINEAR SYSTEMS
ER

PT S
ID SYSTEM
ER

PT B
DE immune system; self; non-self; strings
ER

PT J
ER

PT S
DE bioengineered tissue; immune response
ID SMALL-INTESTINAL SUBMUCOSA; RENAL-ALLOGRAFT REJECTION; INTRAHEPATIC
   ISLET ALLOGRAFTS; TOLL-LIKE RECEPTOR-4; LONG-TERM SURVIVAL; TRYPTOPHAN
   CATABOLISM; IMMUNE-RESPONSE; DENDRITIC CELLS; TRANSPLANTATION TOLERANCE;
   HUMANIZED ANTI-CD154
ER

PT S
DE graft rejection; antigen-presenting cells
ID IMMATURE DENDRITIC CELLS; TRYPTOPHAN CATABOLISM; IMMUNE-RESPONSE;
   TOLERANCE; TRANSPLANTATION; INHIBITION; PREVENTION
ER

PT J
ID T-CELL DEVELOPMENT; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; RECEPTOR-INDUCED
   ACTIVATION; GERMINAL CENTER FORMATION; PROTEIN-TYROSINE KINASES;
   NF-KAPPA-B; DEFICIENT MICE; THYMOCYTE DEVELOPMENT; POSITIVE SELECTION;
   CD40 LIGAND
ER

PT J
ID LINKED LYMPHOPROLIFERATIVE-DISEASE; COMMON VARIABLE IMMUNODEFICIENCY;
   CLASS-II DEFICIENCY; B-CELL DEVELOPMENT; CHEDIAK-HIGASHI-SYNDROME;
   EPSTEIN-BARR-VIRUS; IGA DEFICIENCY; V(D)J RECOMBINATION; TYROSINE
   KINASE; ENCODING GENE
ER

PT J
ER

PT J
ID SINGLE-CHAIN FV; COMPLEMENTARITY-DETERMINING REGIONS; IMMUNOGLOBULIN
   VARIABLE DOMAINS; BISPECIFIC ANTIBODY FRAGMENTS; HUMAN
   MONOCLONAL-ANTIBODIES; HIGH-AFFINITY ANTIBODIES; ESCHERICHIA-COLI;
   COMBINATORIAL LIBRARIES; SYNTHETIC REPERTOIRES; SELECTION-STRATEGIES
ER

PT J
ID HUMAN MONOCLONAL-ANTIBODIES; RESHAPING HUMAN-ANTIBODIES; BY-PASSING
   IMMUNIZATION; 3-DIMENSIONAL STRUCTURE; VARIABLE DOMAINS; TRANSFORMED
   LYMPHOCYTES; SYNTHETIC REPERTOIRES; HUMAN-IMMUNOGLOBULIN; FILAMENTOUS
   PHAGE; 2.8-A RESOLUTION
ER

PT J
ER

PT J
ID TOLERANCE
ER

PT J
ID OPTIMIZATION
ER

PT J
ER

PT J
ID COLONY-STIMULATING FACTOR; MURINE MAMMARY ADENOCARCINOMA; CELL-DEATH;
   IL-2 GENE; INTERLEUKIN-2; INVIVO; RELEASE; MEMORY; UNRESPONSIVENESS;
   IMMUNOGENICITY
ER

EF